Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL-104 for prevention and reduction of oral mucositis after chemotherapy with PBSCT
ISRCTN68967559Phase 2Completed
- Sponsor
- Alizyme
- Start
- Jul 2004
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, double-blind trial of ATL-104 in stomatitis and gastrointestinal mucositis (4 arms), sponsored by Alizyme. Primary endpoints: Adverse events and Oral mucositis scale. Started Jul 2004; status: completed.
02
Drugs
ATL-104
03
Conditions
stomatitisgastrointestinal mucositis
Beyond the preview
Go deeper on ISRCTN68967559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68967559.